DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...

Now, it’s worth noting Stock Advisor's total average return is 1,079% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

ViCentra's Kaleido is "the smallest, thinnest, lightest, most precise insulin patch pump in its class," CEO Tom Arnold said ...

The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin. Biolinq says its ...

In a further comparison using DPP-4i/SU as the reference, the GLP-1 RA/SGLT2i combination therapy had the greatest effect in ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $99.3, a high estimate of $106.00, and a low estimate of $89.00. Marking an ...

VIENNA — Tirzepatide was associated with improvements in body weight and body composition, and with lower insulin doses, in the first-ever randomized controlled trial (RCT) of the drug in people with ...

The FDA has granted de novo classification to the Biolinq Shine wearable biosensor, which would be the first needle-free CGM ...

The FDA said Dexcom issued a correction for certain continuous glucose monitor apps due to a software design error that ...

Global equities are likely to continue edging higher even as valuation concerns continue to arouse fear among investors.

PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large ...